Drugs / PF-06936308
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03674827 | Nov 2018 → Sep 2021 | non-small cell lung carcinoma, triple-negative breast carcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06936308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03674827 ↗ |